Showing results (141-150 of 261) with videos related to

Sort By:
Pageof 27
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Blood|June 9, 2018
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironmentFathima Zumla Cader, Ron C J Schackmann, Xihao Hu, et al.
Blood|June 20, 2012
A disease risk index for patients undergoing allogeneic stem cell transplantationPhilippe Armand, Christopher J Gibson, Corey Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2013
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemiaYi-Bin Chen, Erin Coughlin, Kevin F Kennedy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2010
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Joanna Rhodes, et al.
Blood|July 18, 2013
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trialCorey Cutler, Haesook T Kim, Bhavjot Bindra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand, Haesook T Kim, Vincent T Ho, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II TrialJohn Koreth, Haesook T Kim, Paulina B Lange, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 28, 2014
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host diseaseCaron A Jacobson, Lixian Sun, Haesook T Kim, et al.
Pageof 27